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Abstract
Objective To provide age-specific medial temporal lobe atro-
phy (MTA) cut-off scores for routine clinical practice as mark-
er for Alzheimer’s disease (AD).
Methods Patients with AD (n = 832, mean age 81.8 years)
were compared with patients with subjective cognitive impair-
ment (n = 333, mean age 71.8 years) in a large single-centre
memory clinic. Mean of right and left MTA scores was deter-
mined with visual rating (Scheltens scale) using CT (0, no
atrophy to 4, severe atrophy). Relationships between age and
MTA scores were analysed with regression analysis. For var-
ious MTA cut-off scores, decade-specific sensitivity and spec-
ificity and area under the curve (AUC) values, computed with
receiver operator characteristic curves, were determined.
Results MTA strongly increased with age in both groups to a
similar degree. Optimal MTA cut-off values for the age ranges
<65, 65–74, 75–84 and ≥85 were: ≥1.0, ≥1.5, ≥ 2.0 and ≥2.0.
Corresponding values of sensitivity and specificity were
83.3% and 86.4%; 73.7% and 84.6%; 73.7% and 76.2%;
and 84.0% and 62.5%.
Conclusion From this large unique memory clinic cohort we
suggest decade-specific MTA cut-off scores for clinical use.
After age 85 years, however, the practical usefulness of the
MTA cut-off is limited.
Key Points
• We suggest decade-specific MTA cut-off scores for AD.
• MTA cut-off after the age of 85 years has limited use.
• CT is feasible and accurate for visual MTA rating.
Keywords Alzheimer’s disease . Temporal lobe . Diagnostic
imaging . Computed tomography . Clinical practice
Introduction
Medial temporal lobe atrophy (MTA) is considered as a bio-
marker for Alzheimer’s disease (AD) [1–6] and visual MTA
ratings are available for clinical use [7]. There is debate as to
what cut-off scores should be used in clinical practice to opti-
mally differentiate AD from controls without dementia [8] or
with other types of dementia [9, 10]. One of the main prob-
lems is that MTA increases with age and cut-off scores should
be adjusted for age [11, 12]. However, few studies are avail-
able addressing this issue.
MTA cut-off scores were investigated in two recent studies
that suggest increasing these scores with 0.5 per decade in
elderly patients [12, 13]. If evaluated in clinical settings, these
cut-off values might prove to be an aid in the diagnostic eval-
uation of AD. This testing is necessary since AD patients in
these studies were not representative for those in a general
hospital memory clinic and no data are available on computed
tomography (CT). Furthermore, relatively few patients over
80 years of age were included, and specifically in these elderly
patients MTA differentiation of AD and a reference group
may be problematic due to the age effect [14].
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Therefore, we test these decade-specific MTA cut-off
scores in a single-centre memory clinic population including
a large sample of patients over 80 years of age and assess the
use of MTA in clinical practice. We defined decade-specific
MTA cut-off values that best discriminate between AD and
subjective cognitive impairment (SCI) using CT scans with
visual rating of MTA.
Methods
Subjects
Patients included in this study were referred because of cog-
nitive complaints to the memory clinic at Tergooi Hospital, a
general hospital in Hilversum and Blaricum, The Netherlands.
Since April 2009, we use a standard protocol for diagnostic
assessment, based on the healthcare pathway of the VUmc
Alzheimer Center with organization in a one-stop shop mo-
dality [15]. Each patient received the same diagnostic work-up
in one day, resulting in a total of close to 350 patients per year.
This resulted in a consecutive series of 2,000 patients in a
period of 6 years, from April 2009 to April 2015 (for a sum-
mary of the study population and procedures see Claus et al.
[16]). All patients diagnosed with AD (832) or SCI (333) were
included in the current study.
Clinical diagnostic procedures
All patients completed the following diagnostic evaluation:
(1) a full medical and neurological examination including
history-taking by a neurologist or geriatrician, (2) assessment
of vital functions, (3) cognitive screening with a CAMCOG
test part of the CAMDEX, (4) standard electrocardiogram, (5)
laboratory tests and (6) informant-based history and assess-
ment of needs by a specialized nurse including admission of
the Geriatric Depression Scale (GDS) and assessments of the
Instrumental Activities of Daily Living Scale. The clinical
diagnosis was made in a consensus meeting attended by the
neurologist, geriatrician, neuropsychologist and a specialized
nurse. AD diagnosis was made using the current standard
clinical diagnostic criteria for AD [3]. MTA rating was not
used in the diagnostic procedure.
If patients scored normally on all tests and no other diag-
nosis could be made, patients were considered as having SCI.
These patients were used as the reference group.
Computed tomography (CT) protocol
CT scanning of the brain was performed using a 64-detector
row CT with Siemens Somatom definition AS 64-slice scan-
ner according to a CT brain protocol for the memory clinic
(260 mAs, 120 kV, 64 * 0.6 mm collimation, pitch of 0.55,
WC/WW= 40/80, CARE kV = on (dose optimation slider on
non-contrast)). Oblique coronal, sagittal and transverse recon-
structions were made with bone-window 1.5-mm slices, axial
slices of 5.0 mm and oblique coronal slices of 3.0 mm, mod-
ified from the protocol described byWattjes et al. [17]. All CT
scans were reviewed by a radiologist in the routine procedure
of patients presenting to an outpatient memory clinic to ex-
clude any other underlying disease that could explain cogni-
tive decline. The report of the radiologist was not used in a
structured (MTA) or unstructured way for the diagnosis of AD
at the multidisciplinary meeting.
CT scans were visually assessed for MTA by applying the
5-point rating scale from 0 (no atrophy) to 4 (maximum atro-
phy) as proposed by Scheltens et al. [7]. The right and left
hemisphere were rated separately, the MTA score being the
average of these two values. This visual assessment was made
in a consensus meeting by a neurologist and geriatrician.
Beforehand, these specialists had received instructions on
how to perform anMTA rating according to the original study
by Scheltens et al. [7], by regular visits of Prof. Scheltens to
Tergooi Hospital.
Intra-rater and inter-rater variability was assessed using a
randomly selected set of 20 CTs that was visually rated for
right and left MTA, blinded for age and diagnosis, by two
combinations of the neurologist and geriatrician as employed
for consensus rating in our daily memory clinic practice, as
well as by an experienced neuroradiologist. This allowed
comparison between two teams of neurologist and geriatrician
and of these teams with the radiologist. The same set was rated
1 week later by the same persons allowing intra-rater variabil-
ity testing.
Statistical analysis
We used SPSS version 22.0. Baseline characteristics were
analysed with one-way ANOVA or with chi-square tests when
appropriate. The relationship between age and MTA scores
was assessed with multiple linear regression analysis, with
adjustment for gender and level of education in AD patients
and SCI patients separately. Interaction between age and di-
agnosis in relation to MTA was investigated with two-way
independent ANOVA (general linear model). In other words,
we assessed whether the slopes of the regression lines were
significantly different between groups. In addition, the rela-
tionship between age and MTAwas determined separately in
those aged under and over 80 years to determine specific age-
related effects onMTA scores. Eighty years was chosen as the
age for analysis to define elderly AD patients since in the
literature few data are available on the relationship between
age and MTA above 80 years of age.
The sensitivity and specificity of different MTA cut-off
scores were computed stratified in four decade-specific
groups: <65, 65–74, 75–84, ≥85 years. Statistical analyses
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were performed using chi-square tests. Diagnostic perfor-
mance was further investigated with receiver operator charac-
teristic (ROC) curves with corresponding areas under the
curve (AUC) and 95% confidence intervals. Optimal combi-
nations of sensitivity and specificity were defined according to
the highest AUC value, unless a more favourable combination
of sensitivity and specificity was present for clinical purposes,
i.e. higher specificity to avoid false positives, with a compa-
rable AUC value.
Intra-rater and inter-rater variability were computed using
the intraclass correlation coefficient (ICC) with a two-way
mixed absolute agreement and single-measures design. We
calculated the following ICC values with 95% confidence
interval (CI) for mean of right and left MTA score: (1) intra-
rater reliability for first and second MTA rating for the two
teams of neurologist and geriatrician and for the neuroradiol-
ogist, (2) inter-rater reliability between the first and second
team of neurologist and geriatrician, and (3) inter-rater reli-
ability between either the team of neurologist and geriatrician
and the neuroradiologist.
Results
The clinical characteristics and frequencies of MTA scores are
shown in Table 1. The mean age of the total population was
78.9 years (range 45–96 years). SCI patients had a lower per-
centage of female persons than AD patients (p < 0.01), were
significantly younger (p < 0.001), had a higher level of educa-
tion (p < 0.001) and a higher MMSE score (p < 0.001), and
lower mean MTA than AD patients (Table 1). Regression
analysis showed statistically significant relationships between
age and MTA, adjusted for gender and education for both SCI
and AD patients in separate analyses with regression coeffi-
cients of 0.043 ± 0.004 (p < 0.001) and 0.036 ± 0.004
(p < 0.001), respectively. Interaction analysis showed no dif-
ferential effect of diagnosis on the relationship between age
and MTA (p = 0.26). Thus, the effect of age on MTA was
similar in SCI and AD patients. These relationships were also
computed in those under 80 years of age and in patients of
80 years of age and above. Regression coefficients for SCI
patients were 0.040 ± 0.005 (p < 0.001) and 0.027 ± 0.027
(p = 0.34), respectively, and for AD patients 0.046 ± 0.010
(p < 0.001) and 0.020 ± 0.010 (p < 0.05), respectively.
Regression coefficient values are almost halved in patients
over 80 years of age when compared with those under, and
the relationship between age andMTA is no longer significant
above the age of 80 years in SCI patients, possibly explained
by the lower number of patients in this age group. It thus
appears that the age effect is stronger below 80 hyears than
in 80 years and above but to a similar degree in SCI and AD.
See Fig. 1 for MTA decade-specific values in relation to age
for SCI and AD separately.
The sensitivity and specificity of different MTA decade-
specific cut-off scores are shown in Table 2 and ROC curves
are shown in Fig. 2 (total number of patients 1,158; seven
scans were missing). Optimal decade-specific MTA cut-off
scores were the following: <65 years, MTA cut-off value
≥1.0 with specificity of 86.4%, sensitivity of 83.3% at the
highest AUC value of 84,8; 65–74 years, MTA cut-off value
≥1.5 with specificity of 84.6% and a sensitivity of 73.7% at
the highest AUC value of 79,1; 75–84 years, MTA cut-off
Table 1 Demographic
characteristics and distribution of
medial temporal atrophy scores
All participants SCI AD p values
No. 1165 333 832
Male/female 440/725 146/187 294/538 <0.01
Age, y, mean (SD) 78.9 ± 9.1 71.8 ± 10.2 81.8 ± 6.9 <0.001
Education (Verhage) 4.3 ± 1.5 4.7 ± 1.4 4.2 ± 1.5 <0.001
MMSE 20.6 ± 6.1 27.2 ± 2.3 18.0 ± 5.0 <0.001
MTA 1.8 ± 1.1 0.7 ± (0.8 2.2 ± 0.8 <0.001
MTA score 0, n (%) 161 (13.9%) 148 (44.4%) 13 (1.6%)
0,5 26 (2.2%) 20 (6.0%) 6 (0.7%)
1 210 (18.1%) 98 (29.4%) 112 (13.6%)
1.5 95 (8.2%) 17 (5.1%) 78 (9.5%)
2 293 (25.3%) 35 (10.5%) 258 (31.3%)
2.5 126 (10.9%) 7 (2.1%) 119 (14.4%)
3 181 (15.5%) 7 (2.1%) 174 (21.1%)
3.5 38 (3.3%) 1 (0.3%) 37 (4.5%)
4 28 (2.4%) 0 (0%) 28 (3.4%)
Comparisons of variables were made with one-way ANOVA or with Chi-square test (gender)
SCI subjective cognitive impairment , AD Alzheimer’s disease , MMSE Mini-Mental State Examination , MTA
medial temporal atrophy, Verhage years of education following primary school
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value ≥2.0 with specificity of 76.2% and sensitivity of 73.7%
at an AUC value of 75.0; this value is comparable to the
highest value of 77.6, therefore in this instance we chose for
the cut-off of ≥2.0 instead of ≥1.5 because the higher speci-
ficity and somewhat lower sensitivity are preferred for clinical
use to reduce the number of false positives; ≥85 years MTA
cut-off value ≥2.0 with specificity of 62.5% and a sensitivity
of 84.0% at the highest AUC value of 73.3, although speci-
ficity is low at this cut-off, increasing the cut-off to ≥2.5 would
reduce the AUC value to 67.9 and result in a low sensitivity of
51.4%. Chi-square tests were statistically significant for all
these cut-off values at p < 0.001.
ICC values (95% CI) for intra-rater reliability were 0.98
(0.96–0.99) for the first team of neurologist and geriatrician,
Fig. 1 Medial temporal atrophy
(MTA) scores (visual rating,
Scheltens scale) on computed
tomography in patients with
subjective cognitive impairment
(SCI) and Alzheimer’s disease
(AD) in relation to age. The x-axis
shows age (years), the y-axis
showsmean of right and left MTA
scores (± 1 standard deviation).
Age correlated significantly with
MTA in both SCI and AD
patients, adjusted for gender and
level of education. The effect of
age on MTAwas similar in both
groups and was stronger before
80 years than after 80 years
Table 2 Sensitivity and specificity of different MTA cut-off values in four age decades comparing patients with Alzheimer’s disease and patients with
subjective cognitive impairment
AD vs. SCI <65,y (n = 106) AUC 65–74,y (n = 186) AUC 75–84,y (n = 521) AUC ≥85,y (n = 345) AUC
AD n = 18, SCI n = 88 AD n = 95, SCI n = 91 AD n = 399, SCI n = 122 AD n = 313, SCI n = 32
SN SP SN SP SN SP SN SP
MTA ≥1 83.3 86.4 84.8 94.7 61.5 78.1 97.5 26.2 61.9 99.7 12.5 56.1
MTA ≥1.5 44.4 96.6 70.5 73.7 84.6 79.1 84.0 71.3 77.6 89.8 53.1 71.5
MTA ≥2 22.2 98.9 60.5 57.9 91.2 74.6 73.7 76.2 75.0 84.0 62.5 73.3
MTA ≥2.5 5.6 98.9 52.2 24.2 98.8 61.6 43.4 93.4 68.4 51.4 84.4 67.9
MTA ≥3 0.0 100.0 50.0 11.6 98.9 55.2 27.3 97.5 62.4 38.0 87.5 62.8
MTA ≥3.5 0.0 100.0 50.0 2.1 100.0 51.1 6.5 99.2 52.8 11.8 100.0 55.9
MTA ≥4 0.0 100.0 50.0 2.1 100.0 51.1 3.0 100.0 51.5 4.5 100.0 52.2
Sensitivity (SN) and specificity (SP) values and area under the curve (AUC, computed with receiver operator characteristic curves) for medial temporal
atrophy (MTA) visual rating scale (Scheltens) on computed tomography as marker for patients with Alzheimer’s disease (AD) compared to patients with
subjective cognitive impairment (SCI). MTA (mean of right and left value) is considered positive when MTA is higher or equal to the indicated cut-off
value. For example at MTA ≥1 under 65 years: 83.3% of AD patients and 13.6% of SCI patients had MTA ≥1. Optimal combinations of sensitivity and
specificity are in bold
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0.97 (0.94–0.99) for the second team, and 0.91 (0.79–0.96) for
the neuroradiologist, demonstrating good (ICC value >0.70)
to very good reliability and thus consistent ratings over time.
The ICC value for inter-rater reliability between the two teams
of neurologist and geriatrician was 0.95 (0.89–0.98) showing
good reliability between the two teams. ICC value for inter-
rater reliability between the first team of neurologist and ger-
iatrician and the neuroradiologist was 0.88 (0.73–0.95), and
0.87 (0.71–0.95) for the second team and the neuroradiologist.
These results show good reliability between the teams and the
neuroradiologist.
Discussion
We found that MTA strongly increased with age, but that the
age effect is much stronger below 80 years than above, at the
same rate in both AD patients and patients with SCI. In
Fig. 2 Diagnostic performance of the visual medial temporal atrophy
(MTA) rating scale (Scheltens) with receiver operator characteristic
curves comparing patients with subjective cognitive impairment and
Alzheimer’s disease per age decade. Optimal cut-off values are: ≥1.0
for <65, ≥1.5 for 65–74, ≥ 2.0 for 75–84, and ≥2.0 for ≥85 years
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addition, optimal MTA cut-off scores to differentiate AD from
SCI were ≥1.0, ≥1.5, ≥2.0 and ≥2.0 for the four respective
decades.
Increase of MTA with age showed similar patterns in AD
and controls [18, 19] and atrophy in these groups showed
overlap especially in the hippocampus with increasing age
[20]. However, few subjects over 80 years old are studied
[21], and whether the slopes of the regression lines of age
and MTA diverge, converge or continue to remain parallel
between AD and controls was unknown in these elderly per-
sons. We now demonstrate that the effect of age on MTA is
similar in both AD and SCI, even at advanced age, and that
this effect attenuates after 80 years, again to a similar degree.
This may represent a ceiling effect of the visual MTA rating
scale or a true absence of patients with severe hippocampal
atrophy in our population, possibly explained by selective
referral. When differences between groups remain largely
the same even at high age, MTA may retain its diag-
nostic capacity to differentiate AD from control subjects
or SCI patients in a memory clinic setting in these very
elderly individuals but further analyses in this study do
not support this notion.
MTAvisual rating was proposed by Scheltens et al. in 1992
[7] and since then this scale has been used in research studies,
validated for AD patients [8], incorporated in clinical criteria
[5], modified by several authors [22–24], and shown to be
reproducible among observers [25]. The use of the Scheltens
scale in routine clinical practice is still limited, however, in part
due to lack of validation [26]. The average of right and left
MTA score is suggested as the best marker [12] and recom-
mendations were made for the use of 1.5 under 75 years and 2
or more for those over 75 years as cut-off scores [11]. Only
recently has the approach been taken to compute decade-
specific MTA cut-off scores optimize sensitivity and specific-
ity [13], and these cut-off scores were used in a recent study on
quantitative electroencephalography in addition to dementia
biomarkers [27].We adopted this strategy and tested the results
in a memory clinic setting and found comparable results for the
middle-age ranges, despite methodological differences includ-
ing different AD source population (single-centre memory
clinic vs. academic centres and private practice), different ref-
erence population (patients with SCI versus normal controls),
different rating procedure (consensus rating vs. one single rat-
er) and different imaging tool (CT vs. MRI). With the excep-
tion of the cut-off scores under 65 years and above 85 years of
age [13], MTA decade-specific cut-off values of 1.5 and 2.0
were the same in the age ranges 65–74 years and 75–84 years.
Our study is the first to use a large unselected population of AD
patients in one clinical centre demonstrating that a decade-
specific adjustment is needed for MTA cut-off scores.
Optimal combinations of sensitivity and specificity are
based on the highest value of AUC in studies, for example
in Ferreira et al. [13]. This may not always be the best
approach to define the clinical usefulness of MTA as an in-
strument to support the diagnosis of AD. As clinicians, we
must keep the chance of making a false-positive diagnosis
using MTA as low as possible. In our study it is apparent that
in the age group of 75–84 years the cut-off with the highest
AUC value (77.6) has a high sensitivity of 84.0% but the
corresponding value of specificity is lower and false positive
rates fall close to 30% (MTA ≥ 1.5 in 75–84 years). Therefore,
from a clinical perspective, we increased the cut-off from 1.5
to 2.0 to increase specificity and accept a lower sensitivity.
AUC values from the cut-offs 1.5 and 2.0 are very compara-
ble, 77.6 versus 75.0.
Our finding that the age effect on MTA decelerates after
80 years would suggest not increasing the cut-off after
85 years. Based on the AUC values, this is precisely what
our results suggest with the highest AUC value being 73.3 at
cut-off ≥ 2.0 and corresponding high sensitivity of 84.0% but
low specificity of 62.5%. Increasing the cut-off value to ≥ 2.5
for above 85 years, however, results in our opinion in an
unacceptably low sensitivity value of 51.4%. Therefore,
above 85 years, there is either low specificity (cut-off ≥2.0)
or low sensitivity (cut-off ≥2.5), limiting the practical use of
MTA above the age of 85 years. We suggest using the MTA
cut-off ≥2.0 above the age of 85 years, bearing in mind that
there is the risk of false positives. However, using the data
from Table 2, clinicians may decide themselves how to use
the MTA cut-off scores, e.g. using presence of MTA ≥2.5 for
over 85 years as highly suggestive for AD with a 16% chance
of false positives.
AUC values of our study are generally somewhat lower
than the Ferreira study [13], with a small age effect, with
largest differences in the highest age groups (decade-specific
differences 2.9, 1.7, 4.9 and 5.9 respectively). Since AUC is a
combined measure of sensitivity and specificity, this may be
due to either of these values. It appears that it is not the spec-
ificity that is responsible for this difference, with even higher
specificity values in our study in the suggested cut-off scores
than the Ferreira study, with the exception of the 2.5 cut-off.
Interestingly, this suggests that our SCI group is very much
comparable to the normal control group in the Ferreira study.
In our study sensitivity is lower in all age groups, being con-
stantly 10% lower in all four age groups. Thus the percentage
of AD patients having MTA scores above the cut-off scores is
about 10% higher in the Ferreira study [13], probably ex-
plained by our unselected AD patients referred for evaluation
to a general memory clinic.
Methodological considerations include our use of SCI as
reference group, opposed to the use of normal controls in other
studies. The SCI group may contain patients at risk for cogni-
tive decline or dementia [28] and many may fulfill criteria for
subjective cognitive decline [29]. This may result in
underestimating the difference between groups. Although this
possibility cannot be excluded, it seems unlikely since
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comparison of our SCI patients with the normal controls in the
Ferreira study [13] shows that similarities outweigh differ-
ences with a slightly lower MMSE score but a lower MTA
score in SCI. Moreover, the use of SCI as a reference group
may increase face validity and be more advantageous, since
our study confirms that within the group of referred elderly
patients to a memory clinic, differentiation can be made be-
tween AD and SCI. A mean MMSE score of 18.0 clearly
shows that this study represents the whole range of severity
in a memory clinic population.
Our MTAvisual rating procedure is different from previous
studies. Some of these studies employ a single rater withmuch
experience in the field [12, 13, 30]; however, this procedure is
not easily translated to the general clinical situation. The ad-
vantage of a single rater is high intra-rater reliability as op-
posed to the risk of higher variability with different raters or
with consensus ratings. There is an effect of expertise and
practice in the visual rating of MTA when expert neuro-
radiologists are compared to non-expert readers [31]. But, as
the authors emphasize, in general clinical practice ratings are
often performed by radiologists with less experience, as is the
case in our hospital. Therefore, since expertise plays a crucial
role inMTA ratings, the radiological reports could not be used
as gold standard and we employed a consensus rating by an
experienced neurologist and geriatrician. This rating proce-
dure may be more representative for usual clinical practice
and further supports the generalizability of our findings to
comparable clinical settings.
Another reason for consensus rating is to decrease inter-
individual variability. Our intra-rater variability study shows
reliable and consistent ratings over time for the two teams of
neurologist and geriatrician and for the neuroradiologist. Also
the inter-rater studies show good reliability between all raters,
further adding to the validity of our results. Our study suggests
practical usefulness of MTA and may give impetus to more
routine use of MTA ratings by radiologists and increase expe-
rience in these assessments.
Comparison of visual rating and volumetric measurement
of MTA on MRI has received much investigative attention.
While strenuous efforts are made to develop standardized pro-
tocols for manual segmentation in hippocampal volumetry on
MRI [32, 33], there is a need to test visual rating procedures,
due to its easier use in clinical practice. Indeed, the most fre-
quently used biomarker is visually rated MTA [34]. In
distinguishing AD patients versus normal controls several
studies now indicate that visual rating of MTA on MRI is
equivalent to volumetric measurement [28, 29, 35–37].
AlthoughMRI has higher resolution and provides no radiation
exposure, we used CT in our study as it was earlier suggested
that CT imaging may be equivalent for visual assessment
compared to MRI when a 64-slice CT is used in a practical
clinical situation [17]. Another consideration was that in the
elderly population CT is more easily applicable and
convenient for patients. Our findings thus suggest that CT
may serve as an equivalent imaging tool as MRI in these
elderly individuals for this purpose. This may have important
consequences for clinical practice in memory clinics.
Our study has several limitations. We have no CSF support
for our AD diagnosis and pathological confirmation is not
available. Thus, diagnostic misclassification may play a role
and overestimation ofMTA in the differentiation between SCI
and AD cannot be excluded. Indeed, very old patients with
moderate to severe MTAmay be misdiagnosed since this may
not always reflect Alzheimer-type pathology [38]. Further
studies are needed in terms of test-retest studies, correlation
with clinical measures [26] and post-mortem studies [39].
Ferreira et al. suggest that carrying the ApoE ε4 allele may
have an impact onMTAvalues, showing that ApoE ε4 carriers
had higher MTA scores, but only in those under 65 years of
age [13]. We did not have ApoE genotyping available.
Furthermore, there is the risk that MTA assessments played
a role in making the diagnosis of SCI or AD in our study.
However, MTA ratings were not part of the diagnostic pro-
cess, partly because reliable cut-off values were not available.
Finally, we did not report MTA in relation to mild cognitive
impairment or other dementia diagnoses, such as fronto-
temporal dementia, dementia with Lewy bodies or dementia
with Parkinson’s disease, as this was not the focus of current
study. However, this scope is important in clinical practice and
should receive future investigative attention.
In conclusion, we suggest decade-specific MTA cut-off
scores for Alzheimer’s disease in the elderly. Visual MTA
assessment using CT scans is feasible with high face validity
in a memory clinic setting and these cut-off scores may now
be adopted in routine clinical practice.
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